ERA-NET E-Rare 3 on Rare Diseases: outcome of JTC 2016
Swiss researchers are participating in three projects funded by the ERA-NET E-RARE 3 joint transnational call 2016.
The ERA-NET E-Rare 3 joint transnational call JTC 2016 for proposals focused on clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases. In total, 31 consortium proposals were submitted. After a highly competitive selection process, eight projects were selected for funding. Swiss researchers are participating in three of the funded projects.
Dirk Fischer (University of Basel) is the leading coordinator of the study "TAMDMD", which investigates the effect of tamoxifen in Duchenne muscular dystrophy. Markus Weber (Cantonal Hospital St. Gallen) is a partner in the ROCK-ALS project. This group will study the inhibition of Rho Kinase with Fasudil as disease-modifying treatment in Amyotrophic Lateral Sclerosis (ALS). Dirk Bassler (University Hospital Zurich) is participating in the "ROPROP" study to investigate propranolol for preemptive treatment of threshold retinopathy of prematurity. All three projects will be financially supported by the SNSF in the coming years.